Treatment of acute myocardial infarction (MI) has been advanced considerably in the past
20 years with the advent of acute reperfusion strategies such as thrombolytic therapy or …

Insight into the pathophysiology of myocardial infarction stimulated strategies to reduce peri-
infarct morbidity and mortality rates. A panoply of procedures and therapeutic adventures …

Background Survivors of acute myocardial infarction (MI) complicated by heart failure and/or
resulting in left ventricular dysfunction are at heightened risk for subsequent death and …

Beta-blockers, angiotensin-converting–enzyme (ACE) inhibitors, and aldosterone
antagonists have been shown to reduce the overall risk of death as well as the risk of major …

Objectives: We attempted to compare the effect of an angiotensin-converting enzyme (ACE)
inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic events. Background …

The concept of “cardioprotection” with ACE inhibitors has evolved over the last decade. In
the 1980s, protective benefits of ACE inhibitors in hypertension were established, regression …

The physiological role of the renin angiotensin aldosterone system (RAAS) is to maintain the
integrity of the cardiovascular system. The effect of angiotensin II is mediated via the …

Angiotensin-converting enzyme (ACE) inhibitor therapy has been associated with a
substantial (≥ 20%) reduction in the risk of major ischemic events in two recent clinical trials …

Current guidelines define the standard of care for patients after myocardial infarction (MI),
with particular focus on patients with significant ventricular dysfunction. Inherent in these …

Congestive heart failure (HF) is a common and serious public health problem affecting
approximately 5 million Americans. Recent treatment strategies have focused on attenuating …